These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 7616753)

  • 1. Strategy and planning for chemopreventive drug development: clinical development plans. Chemoprevention Branch and Agent Development Committee. National Cancer Institute.
    Kelloff GJ; Crowell JA; Boone CW; Steele VE; Lubet RA; Greenwald P; Alberts DS; Covey JM; Doody LA; Knapp GG
    J Cell Biochem Suppl; 1994; 20():55-62. PubMed ID: 7616753
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Strategy and planning for chemopreventive drug development: clinical development plans II.
    Kelloff GJ; Crowell JA; Hawk ET; Steele VE; Lubet RA; Boone CW; Covey JM; Doody LA; Omenn GS; Greenwald P; Hong WK; Parkinson DR; Bagheri D; Baxter GT; Blunden M; Doeltz MK; Eisenhauer KM; Johnson K; Knapp GG; Longfellow DG; Malone WF; Nayfield SG; Seifried HE; Swall LM; Sigman CC
    J Cell Biochem Suppl; 1996; 26():54-71. PubMed ID: 9154168
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New agents for cancer chemoprevention.
    Kelloff GJ; Boone CW; Crowell JA; Steele VE; Lubet RA; Doody LA; Malone WF; Hawk ET; Sigman CC
    J Cell Biochem Suppl; 1996; 26():1-28. PubMed ID: 9154166
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemopreventive drug development: perspectives and progress.
    Kelloff GJ; Boone CW; Crowell JA; Steele VE; Lubet R; Sigman CC
    Cancer Epidemiol Biomarkers Prev; 1994; 3(1):85-98. PubMed ID: 8118391
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cancer risk factors for selecting cohorts for large-scale chemoprevention trials.
    Greenwald P
    J Cell Biochem Suppl; 1996; 25():29-36. PubMed ID: 9027595
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemoprevention clinical trials.
    Kelloff GJ; Boone CW; Malone WF; Steele VE
    Mutat Res; 1992 Jun; 267(2):291-5. PubMed ID: 1376431
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Executive Summary of the National Cancer Institute Workshop: Highlights and recommendations.
    Lieberman R; Nelson WG; Sakr WA; Meyskens FL; Klein EA; Wilding G; Partin AW; Lee JJ; Lippman SM
    Urology; 2001 Apr; 57(4 Suppl 1):4-27. PubMed ID: 11295590
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemoprevention of experimental bladder cancer.
    Moon RC; Detrisac CJ; Thomas CF; Kelloff GJ
    J Cell Biochem Suppl; 1992; 16I():134-8. PubMed ID: 1305677
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancer chemoprevention. Part 2: Hormones, nonclassic antioxidant natural agents, NSAIDs, and other agents.
    Singh DK; Lippman SM
    Oncology (Williston Park); 1998 Dec; 12(12):1787-800; discussion 1802, 1805. PubMed ID: 9874850
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Screening for chemopreventive (anticarcinogenic) compounds in rodents.
    Boone CW; Steele VE; Kelloff GJ
    Mutat Res; 1992 Jun; 267(2):251-5. PubMed ID: 1376427
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cancer chemoprevention. Part 1: Retinoids and carotenoids and other classic antioxidants.
    Singh DK; Lippman SM
    Oncology (Williston Park); 1998 Nov; 12(11):1643-53, 1657-8; discussion 1659-60. PubMed ID: 9834941
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanistic considerations in chemopreventive drug development.
    Kelloff GJ; Boone CW; Steele VE; Fay JR; Lubet RA; Crowell JA; Sigman CC
    J Cell Biochem Suppl; 1994; 20():1-24. PubMed ID: 7616736
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemoprevention of OH-BBN-induced bladder cancer in mice by oltipraz, alone and in combination with 4-HPR and DFMO.
    Moon RC; Kelloff GJ; Detrisac CJ; Steele VE; Thomas CF; Sigman CC
    Anticancer Res; 1994; 14(1A):5-11. PubMed ID: 8166455
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biomarker end-points in cancer chemoprevention trials.
    Boone CW; Kelloff GJ
    IARC Sci Publ; 1997; (142):273-80. PubMed ID: 9354926
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Altered expression of c-myc, p16 and p27 in rat colon tumors and its reversal by short-term treatment with chemopreventive agents.
    Tao L; Kramer PM; Wang W; Yang S; Lubet RA; Steele VE; Pereira MA
    Carcinogenesis; 2002 Sep; 23(9):1447-54. PubMed ID: 12189186
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Progress in cancer chemoprevention.
    Kelloff GJ; Crowell JA; Steele VE; Lubet RA; Boone CW; Malone WA; Hawk ET; Lieberman R; Lawrence JA; Kopelovich L; Ali I; Viner JL; Sigman CC
    Ann N Y Acad Sci; 1999; 889():1-13. PubMed ID: 10668477
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemoprevention trials and surrogate end point biomarkers in the cervix.
    Mitchell MF; Hittelman WK; Lotan R; Nishioka K; Tortolero-Luna G; Richards-Kortum R; Wharton JT; Hong WK
    Cancer; 1995 Nov; 76(10 Suppl):1956-77. PubMed ID: 8634987
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intermediate biomarkers of precancer and their application in chemoprevention.
    Kelloff GJ; Malone WF; Boone CW; Steele VE; Doody LA
    J Cell Biochem Suppl; 1992; 16G():15-21. PubMed ID: 1469895
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemoprevention of respiratory-tract neoplasia in the hamster by oltipraz, alone and in combination.
    Moon R; Rao K; Detrisac C; Kelloff G; Steele V; Doody L
    Int J Oncol; 1994 Mar; 4(3):661-7. PubMed ID: 21566974
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A quantitative angiogenesis model for efficacy testing of chemopreventive agents.
    Sharma S; Ghoddoussi M; Gao P; Kelloff GJ; Steele VE; Kopelovich L
    Anticancer Res; 2001; 21(6A):3829-37. PubMed ID: 11911254
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.